Genetic polymorphisms of CYP2E1, GSTP1, NQO1 and MPO and the risk of nasopharyngeal carcinoma in a han Chinese population of Southern China

BMC Research Notes

Volumn 3, Issue , 2010, Pages

  Guo, Xiuchan ^a,b   Zeng, Yi ^a   Deng, Hong ^c   Liao, Jian ^d   Zheng, Yuming ^c   Li, Ji ^e   Kessing, Bailey ^b   O'Brien, Stephen J ^e  

^a Centers for Disease Control   (China)

^b SAIC FREDERICK INC   (United States)

^c Wuzhou Red Cross Hospital   (China)

^d Cangwu Institute for Nasopharyngeal Carcinoma Control and Prevention   (China)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955574444     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-3-212     Document Type: Article

References (25)

1. Analysis and forecast of incidence and mortality of nasopharynx cancer by time series in Zhongshan city. JJ Wu H Guo R Su, Chinese Journal of Hospital Statistics 2001 8 1 16 19
2. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. WH Jia QH Huang J Liao W Ye YY Shugart Q Liu LZ Chen YH Li X Lin FL Wen,, et al. BMC cancer 2006 6 178 10.1186/1471-2407-6-178 16822324
3. Genetic factors leading to chronic Epstein-Barr virus infection and nasopharyngeal carcinoma in South East China: study design, methods and feasibility. XC Guo K Scott Y Liu M Dean V David GW Nelson RC Johnson HH Dilks J Lautenberger B Kessing,, et al. Hum Genomics 2006 2 6 365 375 16848974
4. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. X Guo RC Johnson H Deng J Liao L Guan GW Nelson M Tang Y Zheng G de The SJ O'Brien,, et al. International journal of cancer 2009 124 12 2942 2947 10.1002/ijc.24293
5. Genetic polymorphisms and head and neck cancer risk (Review). T Hiyama M Yoshihara S Tanaka K Chayama, Int J Oncol 2008 32 5 945 973 18425322
6. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. T Oyama T Kawamoto T Mizoue K Sugio Y Kodama T Mitsudomi K Yasumoto, Anticancer research 1997 17 1B 583 587 9066584
7. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. J Sarmanova K Benesova I Gut V Nedelcheva-Kristensen L Tynkova P Soucek, Hum Mol Genet 2001 10 12 1265 1273 10.1093/hmg/10.12.1265 11406608
8. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. A Hildesheim LM Anderson CJ Chen YJ Cheng LA Brinton AK Daly CD Reed IH Chen NE Caporaso MM Hsu,, et al. Journal of the National Cancer Institute 1997 89 16 1207 1212 10.1093/jnci/89.16.1207 9274915
9. Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study. N Kongruttanachok S Sukdikul S Setavarin V Kerekhjanarong P Supiyaphun N Voravud Y Poovorawan A Mutirangura, BMC cancer 2001 1 4 10.1186/1471-2407-1-4 11389775
10. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. D Ryberg V Skaug A Hewer DH Phillips LW Harries CR Wolf D Ogreid A Ulvik P Vu A Haugen, Carcinogenesis 1997 18 7 1285 1289 10.1093/carcin/18.7.1285 9230269
11. Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis. KM Egan Q Cai XO Shu F Jin TL Zhu Q Dai YT Gao W Zheng, Cancer Epidemiol Biomarkers Prev 2004 13 2 197 204 10.1158/1055-9965.EPI-03-0294 14973092
12. Prevalence of the inactivating 609C - >T polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. RA Larson Y Wang M Banerjee J Wiemels C Hartford MM Le Beau MT Smith, Blood 1999 94 2 803 807 10397748
13. Predisposition towards urolithiasis associated with the NQO1 null-allele. WA Schulz A Krummeck I Rosinger BJ Schmitz-Drager H Sies, Pharmacogenetics 1998 8 5 453 454 10.1097/00008571-199810000-00011 9825838
14. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. FJ Piedrafita RB Molander G Vansant EA Orlova M Pfahl WF Reynolds, J Biol Chem 1996 271 24 14412 14420 10.1074/jbc.271.24.14412 8662930
15. Biosynthesis, processing, and sorting of human myeloperoxidase. M Hansson I Olsson WM Nauseef, Arch Biochem Biophys 2006 445 2 214 224 10.1016/j.abb.2005.08.009 16183032
16. Point: myeloperoxidase -463G - > a polymorphism and lung cancer risk. A Feyler A Voho C Bouchardy K Kuokkanen P Dayer A Hirvonen S Benhamou, Cancer Epidemiol Biomarkers Prev 2002 11 12 1550 1554 12496042
17. Myeloperoxidase promotor polymorphism and risk of hepatoblastoma. S Pakakasama TT Chen W Frawley C Muller EC Douglass GE Tomlinson, International journal of cancer 2003 106 2 205 207 10.1002/ijc.11191 (Pubitemid 36835172)
18. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. SH Olson MD Carlson H Ostrer S Harlap A Stone M Winters CB Ambrosone, Gynecol Oncol 2004 93 3 615 620 10.1016/j.ygyno.2004.03.027 15196853
19. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. RJ Hung P Boffetta P Brennan C Malaveille U Gelatti D Placidi A Carta A Hautefeuille S Porru, Carcinogenesis 2004 25 6 973 978 10.1093/carcin/bgh080 14729580 (Pubitemid 38886083)
20. Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. H Dally K Gassner B Jager P Schmezer B Spiegelhalder L Edler P Drings H Dienemann V Schulz K Kayser,, et al. Int J Cancer 2002 102 5 530 535 10.1002/ijc.10756 12432558
21. Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk. MB Schabath MR Spitz GL Delclos GB Gunn LW Whitehead X Wu, Am J Ind Med 2002 42 1 29 37 10.1002/ajim.10084 12111688
22. Myeloperoxidase promoter region polymorphism and lung cancer risk. X Wu MB Schabath MR Spitz, Methods Mol Med 2003 75 121 133 12407737
23. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. MB Schabath MR Spitz WK Hong GL Delclos WF Reynolds GB Gunn LW Whitehead X Wu, Lung Cancer 2002 37 1 35 40 10.1016/S0169-5002(02)00034-X 12057865
24. Cancer Genome Anatomy Project SNP500Cancer Database. 2008
25. No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2, and nasopharyngeal carcinoma in Taiwan. YJ Cheng YC Chien A Hildesheim MM Hsu IH Chen J Chuang J Chang YD Ma CT Luo WL Hsu,, et al. Cancer Epidemiol Biomarkers Prev 2003 12 2 179 180 12582034